<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <title>Research</title>
    <style>
        body {
            font-family: Georgia, serif;
            background-color: #ffffff;
            color: #000000;
            margin: 0;
            padding: 2rem;
            line-height: 1.6;
        }
        .container {
            max-width: 800px;
            margin: 0 auto;
        }
        h1 {
            font-size: 2rem;
            margin-bottom: 1.5rem;
        }
        h2 {
            font-size: 1.5rem;
            margin-top: 2rem;
            margin-bottom: 1rem;
            border-bottom: 1px solid #ccc;
            padding-bottom: 0.25rem;
        }
        .paper {
            margin-bottom: 2rem;
        }
        .paper-title {
            font-size: 1.2rem;
            font-weight: bold;
            margin-bottom: 0.2rem;
        }
        .paper-authors {
            font-size: 0.95rem;
            font-weight: normal;
            color: #444;
            margin-bottom: 0.5rem;
        }
        .abstract {
            display: none;
            margin-top: 0.5rem;
        }
        .button-row {
            margin-top: 0.5rem;
        }
        .toggle-button, .pdf-button {
            background: none;
            border: none;
            color: #0066cc;
            cursor: pointer;
            padding: 0;
            font-size: 1rem;
            text-decoration: underline;
            margin-right: 1rem;
        }
        @media (max-width: 600px) {
            body {
                padding: 1rem;
            }
        }
    </style>
    <meta name="viewport" content="width=device-width, initial-scale=1.0, shrink-to-fit=no">
    <title>Research</title>
    <link rel="stylesheet" href="assets/bootstrap/css/bootstrap.min.css?h=2f5017592099803165df0ae6050729c8">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Montserrat:400,400i,700,700i,600,600i">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/baguettebox.js/1.10.0/baguetteBox.min.css">
    <link rel="stylesheet" href="assets/css/styles.min.css?h=ebd6f95904009a297a139802d395213f">
</head>
<body>
<nav class="navbar navbar-light navbar-expand-lg fixed-top bg-white clean-navbar">
    <div class="container"><a class="navbar-brand logo" href="#">Grady Killeen</a><button data-toggle="collapse" class="navbar-toggler" data-target="#navcol-1"><span class="sr-only">Toggle navigation</span><span class="navbar-toggler-icon"></span></button>
        <div class="collapse navbar-collapse" id="navcol-1">
            <ul class="navbar-nav ml-auto">
                <li class="nav-item"><a class="nav-link" href="index.html">Home</a></li>
                <li class="nav-item"><a class="nav-link active" href="research.html">Research</a></li>
            </ul>
        </div>
    </div>
</nav>
<div class="container">

    <h1> &nbsp; </h1>
    <h1> &nbsp; </h1>
            <h2>Working Papers</h2>
        <div class='paper'>
            <div class='paper-title'>Pharmacy Benefit Managers and Vertical Relationships in Drug Supply: State of Current Research</div>
            <div class='paper-authors'>with Zarek Brot and Benjamin Handel</div>
            <div class='button-row'>
            <button class='toggle-button' onclick='toggleAbstract(this)'>Abstract</button>
            <a class='pdf-button' href='https://www.nber.org/papers/w29959' target='_blank'>Paper</a>
            </div>
            <div class='abstract'><p>Despite their importance to the supply of prescription drugs, there has been limited research on pharmacy benefit managers (PBMs) and their vertical relationships to insurers and drug manufacturers. This paper provides an overview of the current state of research on this topic, motivates why further research is needed, and discusses promising theoretical and empirical directions for that research.</p></div>
        </div>
        <div class='paper'>
            <div class='paper-title'>Investing in Vaccines to Mitigate Harm from COVID-19 and Future Pandemics</div>
            <div class='paper-authors'>with Rachel Glennerster, Sarrin M. Chethik, Claire T. McMahon and Christopher M. Snyder</div>
            <div class='button-row'>
            <button class='toggle-button' onclick='toggleAbstract(this)'>Abstract</button>
            <a class='pdf-button' href='https://www.nber.org/papers/w32984' target='_blank'>Paper</a>
            </div>
            <div class='abstract'><p>This paper evaluates the social value of investing in vaccine research, development, and manufacturing capacity for pandemic preparedness and response. Rapid vaccination during pandemics can significantly reduce mortality, economic losses, and societal disruptions. However, vaccine manufacturers often lack sufficient incentives for speed and capacity expansion. Strategic policies by governments and international organizations could enhance these incentives and improve equitable vaccine distribution.</p></div>
        </div>
        <h2>Work in Progress</h2>
        <div class='paper'>
            <div class='paper-title'>Are two monopolists better than one? Countervailing market power in prescription drug pricing</div>
            <div class='paper-authors'><b>Job Market Paper</b></div>
            <div class='button-row'>
            <button class='toggle-button' onclick='toggleAbstract(this)'>Abstract</button>
            </div>
            <div class='abstract'><p>In the US prescription drug market, there is a growing gap between the price that drug manufacturers set and what they actually receive. This gap is often attributed to the middlemen, called pharmacy benefit managers (PBMs), who are responsible for negotiating confidential discounts on behalf of insurers. One consequence of this growing gap is what consumers may pay in cost-sharing (co-pay or co-insurance), which are indexed to list price, has been growing faster than the net-of-rebate price received by drug manufacturers. This suggests the potential for welfare losses due to a “doubly” marked-up list price: one mark-up by the drug manufacturer and another by the PBM. In this project, I estimate a vertical model of rebate negotiation and drug price setting and use it to assess the drivers of recent pricing patterns, as well as shed light on the role of the PBMs. I find that whether PBMs are welfare enhancing or degrading depends on what the alternative is. Relative to a counterfactual where drug manufacturers set and receive the monopoly price, PBMs can indeed provide a “countervailing” market force that benefits consumers and insurers. However, relative to a counterfactual where the government negotiates prices directly, as Medicare has started to do recently, PBMs do not provide welfare improvements.</p></div>
        </div>
<h1>&nbsp;</h1>

<script>
    function toggleAbstract(button) {
        const abstract = button.closest('.paper').querySelector('.abstract');
        const isVisible = abstract.style.display === 'block';
        abstract.style.display = isVisible ? 'none' : 'block';
        button.textContent = isVisible ? 'Abstract' : 'Abstract';
    }
</script>
</body>
<script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.5.1/jquery.min.js"></script>
<script src="https://cdnjs.cloudflare.com/ajax/libs/twitter-bootstrap/4.6.0/js/bootstrap.bundle.min.js"></script>
<script src="https://cdnjs.cloudflare.com/ajax/libs/baguettebox.js/1.10.0/baguetteBox.min.js"></script>
<script src="assets/js/script.min.js?h=037c4117326bceadaedc2681de8afadc"></script>
</html>
